Health Canada changes filing requirements for product monographs: Notice
March 10, 2023
Our file number: 23-101262-834
Effective immediately, Health Canada is changing the submission requirements for second language product monographs for human drugs.
The second language product monograph is no longer required at the time of submission filing or during review if it is available in both official languages on the:
This change applies to product monographs for the following product types:
- biologic drugs (Schedule D)
- radiopharmaceuticals (Schedule C)
- pharmaceutical drugs (prescription and non-prescription)
Labels and package inserts are not part of this change.
The final second language product monograph must still be submitted following the issuance of the notice of compliance (NOC), drug identification number (DIN) or no objection letter (NOL).
The second language product monograph is still required, as set out in the plain language labelling guidance for prescription and non-prescription drugs, if it is:
- available in only 1 language on the DPD and DHPP or
- for a product that has not yet been authorized
| Product monograph (PM) available on DPD Online | At time of filing | During review | Post-authorization |
|---|---|---|---|
| None | Both official languages preferred Minimum is first language PM |
Second language PM (if not already provided) | Final second language PM |
| One official language PM only | Both official language PMs preferred Minimum is first language PM |
Second language PM (if not already provided) | Final second language PM |
| Both official language PMs | First language PM only | N/A | Final second language PM |
Page details
- Date modified: